YM Bio. Com Shs Share Discussion Threads

[rambutan2] 05/2/2006 14:39

well, the above article has certainly done its job and attracted a bit more attention in north america. ym/ymi/ymba ended the week at all time highs on its respective mkts.

[Abuse team] 03/2/2006 03:40

Post removed by ADVFN

[rambutan2] 30/1/2006 01:44

serratia, re ot:

has had some heavyweight vc backing. but bio listings have had a tendency to drop after coming to mkt, so will leave alone for time being.

re ymba summary. have just tried but failed to do a quick sum up. just doesn't work beyond a v basic view that mkt cap is too small for co with a phase III cancer drug, with lower failure risk than usual, reporting first results mid 06 and with fda permission to finish there and then if they good enough. beyond that it has a v interesting cuban developed humanized, EGF receptor-targeting monoclonal antibody, called nimotuzumab, which is in various trials around the world. they are also have a cancer pain drug which is in trials. etc etc etc etc... to my mind the mkt cap doesn't reflect any of this fully and therefore offers the chance for the shareprice to multiply on favourable results/investor recognition.

sorry, there's no way round it, you need to carefully go through their website and the other sources to try and get ones head round it.

[serratia] 29/1/2006 23:02

Off topic,

There's a company floating tomorrow Incytech I think .Any views a cure for baldness and wrinkles.

[serratia] 27/1/2006 20:45

rambutan2,

A quiet site so a few comments/thoughts. I'm in a fair few oilers and a few Pharmas. Used to work in the industry some time back so I keep an eye on the area. I have aventis shares hoping that accomplia gets approval,in OXB as I like the technology but unsure of the management,in PSG like the technology + a few others.What attracts you to this one I have to say there is rather a lot of info.If you have time can you distill it into a para or two.

[rambutan2] 26/1/2006 12:11

there was a visitor! nice of you to have popped in serratia. and thankyou ym for releasing the news on the lse this time!


YM Biosciences' subsidiary DELEX Therapeutics announces enrollment of

first patient in Phase IIb trial for the treatment of acute pain with

AeroLEF(TM)


MISSISSAUGA, ON, Jan. 26 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), the cancer product development company, today announced that its

subsidiary, DELEX Therapeutics Inc., has enrolled the first patient for its

randomized 120-patient Phase IIb trial for the treatment of moderate to severe

acute pain with AeroLEF(TM). AeroLEF(TM) is a proprietary formulation of free

and liposome-encapsulated nebulized fentanyl, which permits delivery through

the lung. AeroLEF(TM) provides personalized, patient- controlled analgesia to

address the unpredictable variability in analgesic needs that are a hallmark

of acute pain episodes, including breakthrough cancer pain.

The current Phase IIb study is randomized, double-blinded, and

placebo-controlled, and is designed to evaluate the safety and efficacy of

multiple doses of AeroLEF(TM) for management of pain in post-surgical patients

following elective orthopedic surgeries. The trial, for which seven of the

eight clinical sites have been initiated, is expected to enroll approximately

120 patients, complete recruitment and report in the first half of 2006. The

primary endpoint for this study is the Summed Pain Relief plus Pain Intensity

Difference (SPRID) scores during the first four hours after the start of the

initial dose. Secondary endpoints include Time to Effective Pain Relief, as

well as six safety endpoints.

In a previous single dose Phase IIa study, 95% of post-surgical patients

achieved clinically meaningful analgesia following self-administration of

AeroLEF(TM) to treat their moderate to severe pain. Patients reported rapid

onset of analgesia followed by an extended duration of pain relief.

[serratia] 14/1/2006 23:27

Rambutan2,

Not in this but may do if I have time to do a review. You have my admiration as you plough a lone furrow on this thread.

[rambutan2] 14/1/2006 22:56

Here is what is due in Q1 06:

1) Approval for European pediatric glioma nimo phase III of nimo
2) Approval for US pivotal adult glioma nimo phase III
3) Pancreatic cancer results for nimo
4) Stomach cancer trial initiation for tesmilifene
5) Pediatric glioma results
6) Initiation of phase IIb Aerolef
7) Initiation of SWOG phase III in HRPC for tesmilifene

[rambutan2] 13/1/2006 02:25

canaccord ups target again, to still v conservative C$6.94 ...

[rambutan2] 29/11/2005 03:04

latest canaccord buy note of 15/11/05 available on...

[rambutan2] 28/10/2005 23:40

latest canaccord daily letter dated 29/09/05 is available...

with target price of C$6.35 - see their european life sciences review of 16/09/05 for the real detail.

[rambutan2] 13/10/2005 20:07

just the normal positive news...

MISSISSAUGA, ON, Oct. 13 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), the cancer product development company, today announced the

publication of a research paper in the November 2005 issue of the Journal of

Urology that reports results from a Phase II trial of tesmilifene plus

mixantrone/prednisone for the treatment of hormone refractory prostate cancer.

The paper reported that the prostate specific antigen (PSA) decrease and

reduction of symptoms observed with tesmilifene plus mitoxantrone/prednisone

compare favorably to those of mitoxantrone/prednisone and

docetaxel/estramustine in the literature and that the 2-year survival rate of

21% mandates further assessment in a Phase III trial.

'The high proportion of patients experiencing a 50% and 75% PSA decrease,

and dramatic amelioration of pain suggests that this novel regimen may be more

effective than mitoxantrone-prednisone alone, especially when the

characteristics of advanced age and extensive bony metastases are considered.

This novel combination therapy shows sufficient activity to merit formal phase

III testing,' noted Dr. Derek Raghavan, lead author of the paper entitled

'Phase II Trial of tesmilifene plus mixantrone and prednisone for Hormone

Rrefractory Prostate Cancer: High Subjective and Objective Response in

Patients with Symptomatic Metastases.'

[rambutan2] 10/10/2005 10:57

from a us board by a trustable poster...

The Stanford Group just put out a great report on YMI on Sept 29th...They think there is an excellent chance the trials could be stopped early (Feb/March) and an NDA filed by mid 2006...
They have a $6 price target which is very modest IMHO...

[_dan_] 03/10/2005 21:52

sorry if this is old news, must admit I have not looked

[rambutan2] 28/9/2005 08:38

very encouraging...

- Nimotuzumab (Theraloc; TheraCIM h-R3) Phase II results awarded best

poster prize at the 37th congress of the International Society of

Paediatric Oncology -



MISSISSAUGA, ON, Sept. 27 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), the cancer product development company, today announced that

updated data from a Phase II monotherapy trial of nimotuzumab in children with

resistant or relapsed high-grade gliomas (brain cancers) were reported in a

poster presented on September 23rd, 2005 at the 37th Congress of The

International Society of Paediatric Oncology in Vancouver, Canada. Nimotuzumab

produced cytotoxic efficacy and evidence of survival benefit in children with

heavily pretreated relapsed high grade gliomas, especially those with diffuse,

intrinsic pontine glioma.

The presentation updated data originally contained in a press release by

YM BioSciences issued on February 28th, 2005 that described results in 17

evaluable children. The updated data now includes results from 34 children of

which 27 were evaluable at an eight week assessment. The trial design

evaluates the children after eight weeks (induction) of therapy and after week

21 (consolidation) of therapy.

Nine of the 27 patients evaluable following induction had brain-stem

(diffuse intrinsic pontine) glioma, a treatment-resistant tumor. In the nine

evaluable patients with pontine glioma, five demonstrated clinical benefit at

week eight; four with Stable Disease (SD) and one with Partial Response (PR).

At the same time-point, three of the 18 remaining patients diagnosed with high

grade gliomas (grades III/IV) were assessed with clinical benefit (SD) at week

eight.

Of the five patients (all pontine gliomas) who went on to complete the

consolidation period of five months of treatment, two who were evaluated at

induction with SD are now assessed as PR.

Survival in the eight patients who derived clinical benefit post-

induction is as follows:



-------------------------------------------------------------------------

Pontine Glioma Other High-Grade Gliomas

-------------------------------------------------------------------------

Months of Survival 15.5+; 14+; 11; 10; 3+ 11+; 2.5; 8+

-------------------------------------------------------------------------

(+ remains alive)

Median survival of the children who did not respond to nimotuzumab was

1.3 months.



The conclusions of the presentation were:



- Nimotuzumab has cytotoxic efficacy in heavily pretreated relapsed

high grade gliomas, especially in diffuse, intrinsic pontine glioma.



- Repeated application of nimotuzumab is well tolerated and safe; no

severe hematological or non-hematological side effects were reported.



- High quality of life with long intervals of home care, attending the

school or kindergarten.



- A phase III study on the effectiveness of nimotuzumab in newly

diagnosed intrinsic pontine glioma concomitant with radiotherapy in

children and adolescents is planned.



'This study demonstrated the strong anti-tumour activity of nimotuzumab

in the absence of the toxicities, namely rash and diarrhea, normally

associated with other drugs in this class,' said Dr. Paul Keane, Director of

Medical Affairs at YM BioSciences.

The poster presentation was awarded best poster prize at the conference

in the section 'Experimental Therapeutics'. Posters were judged based on

scientific merit, visual presentation and the potential significance of the

clinical research.

[rambutan2] 21/9/2005 10:30

"we believe that ym represents a compelling small-cap opportunity, and we reiterate our buy recommendation" say canaccord in their latest european life science note, which is available in the advfn research section. they have upped their target price to C$6.53 (from C$5.48 in may).